YH 25487
Alternative Names: YH-25487Latest Information Update: 08 Oct 2021
At a glance
- Originator Yuhan
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma
Most Recent Events
- 05 Oct 2021 YH 25487 is available for licensing as of 05 Oct 2021 (Yuhan website, October 2021)
- 01 Oct 2021 Preclinical trials in Asthma in South Korea (unspecified route) (Yuhan Pipeline, September 2021)